Merck, Inc.
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT05877547
- Locations
- 🇺🇸
Indago Research & Health Center, Inc ( Site 3207), Hialeah, Florida, United States
🇺🇸Sweet Hope Research Specialty, Inc-Research ( Site 3200), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research, Syracuse ( Site 3227), East Syracuse, New York, United States
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT05853367
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0101), Toronto, Ontario, Canada
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇨🇦Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100), Montréal, Quebec, Canada
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 390
- Registration Number
- NCT05845814
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 3106), Toronto, Ontario, Canada
🇺🇸Emory University School of Medicine ( Site 3043), Atlanta, Georgia, United States
🇨🇱Bradfordhill-Clinical Area ( Site 3155), Santiago, Region M. De Santiago, Chile
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT05818137
- Locations
- 🇯🇵
Hokkaido University Hospital ( Site 2001), Sapporo, Hokkaido, Japan
🇯🇵Chiba Saiseikai Narashino hospital ( Site 2004), Narashino, Chiba, Japan
🇯🇵Nagoya University Hospital ( Site 2010), Nagoya-Shi, Aichi, Japan
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 162
- Registration Number
- NCT05818124
- Locations
- 🇬🇧
hVIVO Services ( Site 0001), London, London, City Of, United Kingdom
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05769595
- Locations
- 🇯🇵
Jomo Ohashi Clinic ( Site 1210), Maebashi, Gunma, Japan
🇯🇵Keiaikai Nakamura Hospital ( Site 1213), Beppu, Oita, Japan
🇯🇵Kasugai Municipal Hospital ( Site 1203), Kasugai, Aichi, Japan
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05766501
- Locations
- 🇺🇸
Mills Clinical Research ( Site 3114), Los Angeles, California, United States
🇨🇦Maple Leaf Research ( Site 1301), Toronto, Ontario, Canada
🇺🇸Kaiser Permanente ( Site 3124), Los Angeles, California, United States
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05763823
- Locations
- 🇨🇳
Institute of hematology&blood disease hospital-Hematology ( Site 0030), Tianjin, Tianjin, China
🇨🇳Shenzhen Second People's Hospital-Hematology Department ( Site 0006), Shenzhen, Guangdong, China
🇨🇳The First Affiliated Hospital of Soochow University-hematology department ( Site 0029), Suzhou, Jiangsu, China
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 377
- Registration Number
- NCT05722015
- Locations
- 🇭🇺
Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan
🇺🇸St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 342
- Registration Number
- NCT05714085
- Locations
- 🇲🇽
Instituto Nacional de Cardiologia Ignacio Chavez ( Site 1804), Mexico, Mexico
🇵🇱Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 2302), Gdańsk, Pomorskie, Poland
🇺🇸Loma Linda University Health System ( Site 0008), Loma Linda, California, United States